VANCOUVER, BC and LAS VEGAS, NV / ACCESSWIRE / March 17, 2020 / Ovation Science Inc. (CSE:OVAT) (“Ovation” or the “Company”), announces that it has shipped its second order of DermSafe® hand sanitizer lotion to China from a new client in addition to shipping three orders in the last week and an additional order this week to England; all by air as the demand is escalating.
Due to the seriousness and virulence of the COVID-19 virus, Ovation Science has seen heightened demand for its long-lasting chlorhexidine gluconate hand sanitizing lotion called DermSafe. The hand sanitizer does not contain alcohol. It is specially formulated with chlorhexidine gluconate; an ingredient used worldwide in hospitals as it has a proven ability to kill both bacteria and viruses. DermSafe binds to the hands and resists wash-off and rub-off for up to 4 hours post application while continuing to kill both bacteria and viruses.
“It is a very uncertain time as the spread of the coronavirus continues and is escalating in Europe and now also in North America,” said Terry Howlett, President of Ovation. “We are pleased that our suppliers are working with us as we continue to order large inventories of raw ingredients and packaging material to manufacture DermSafe. We want to be able to provide our hand sanitizer as quickly as possible as the demand continues to rise.”
Why DermSafe is in Demand:
- Prevention is key to stop the spread of the COVID-19 virus; alcohol does not have preventive properties while DermSafe has persistent kill of bacteria and viruses for 4 hours, even with hand washing;
- Chlorhexidine gluconate, the ingredient in DermSafe, has been safely used globally for over 50 years and is known to kill both bacteria and viruses;
- DermSafe has been independently tested proving it kills envelope viruses for four hours: H1N1, H5N1, and H3N2. Although it has not been tested, the coronavirus COVID-19 is also an envelope virus;
- DermSafe has been approved and safely marketed in Canada and recently exported to China and the United Kingdom. DermSafe is not approved for sale in the USA.
The WHO (World Health Organization) “Novel Coronavirus (2019-nCoV) Situation Report 55”, as of March 15, 2020 reports there were 153,517 confirmed cases of people with the Coronavirus, up 40% from when we last reported on March 9th; WHO reports 5,735 deaths and it has spread to 143 countries. The WHO Global Risk Assessment to China – Regionally – Globally all remain “VERY HIGH”. WHO declared a pandemic on March 11th.
For information about Ovation Science products visit https://ovationscience.com/products/.
Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
To learn more about Ovation Science, please visit:
www.ovationscience.com for corporate information
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
FOR INVESTOR RELATIONS:
Doug Kerr: email@example.com Phone 604.315.4400
FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:
Doreen McMorran: firstname.lastname@example.org Phone: 604.283.0903 ext. 4
SOURCE: Ovation Science Inc.
View source version on accesswire.com: